Navigation Links
Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C

rd of care alone, which could translate into improved clinical outcomes with longer treatment periods. In addition, the level of antiviral activity from 500mg to 1500mg provides flexibility in selecting doses for future clinical studies."

R7128 Phase 1 Combination Study Overview

The Phase 1 combination clinical trial was a multiple center, observer- blinded, randomized and placebo-controlled study that was conducted in 50 treatment-naive patients chronically infected with HCV genotype 1. The primary objective was to assess the safety, tolerability and pharmacokinetics of R7128 in combination with Pegasys plus Copegus. The secondary objective was to evaluate the change in HCV RNA after 4 weeks of treatment.

The study investigated two oral dose levels of R7128, 500mg and 1500mg, each administered twice-daily (BID) with once-weekly injections of Pegasys plus Copegus. Each cohort of 25 patients was comprised of 20 patients receiving active R7128 and 5 patients receiving placebo with Pegasys plus Copegus (standard of care). The initial evaluation period reported is 4 weeks.

Preliminary Antiviral Activity Summary

Combined Placebo + R7128 500mg + R7128 1500mg +

Pegasys plus Pegasys plus Pegasys plus

Copegus Copegus Copegus

(Standard of Care) (n=20) (n=20)


Mean Decrease in

HCV RNA (log10 IU/mL)

at 4 Weeks -2.95 -3.82 -5.12

Percentage of Patients

with Undetectable

HCV RNA (<15 IU/mL)

at 4 Weeks (RVR) 10% 30% 85%

Potent antiviral activity was demonstrated following 4 weeks of treatment with R7128 1500mg BID with Pegasys plus Copegus, in which patients achieved a mean 5.12 log10 IU/mL decrease in HCV

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
2. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
3. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
4. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
5. Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF
6. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
8. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
9. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
10. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
11. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
Post Your Comments:
(Date:10/9/2015)... Mass. , Oct. 9, 2015  Insulet Corporation ... insulin pump technology with its OmniPod ® ... financial results for the third quarter of 2015 on ... markets. In connection with the release, management will host ... Time). . A replay will ...
(Date:10/9/2015)... 9, 2015 ... The report summarizes key statistics of ... of the manufacturers making it a ... for companies and individuals interested in ... . --> ...
(Date:10/9/2015)... 9, 2015  Impax Laboratories, Inc. (NASDAQ: IPXL ... third quarter 2015 financial results on Monday, November 9, ... markets. The Company will host a conference call and ... Eastern Time on November 9, 2015.  ... The financial results and live webcast will be ...
Breaking Medicine Technology:
... announces that a new market ... Pharmaceutical Contract Manufacturing: World ... Report Details ... contract manufacturing market perform from 2011? Our ...
... September 26, 2011 PharmaVentures, ... the new definitive analysis on the dealmaking and financial ... The first release of this monthly report ... Pfizer has overtaken GlaxoSmithKline and are now placed second ...
Cached Medicine Technology:
(Date:10/9/2015)... ... 09, 2015 , ... Santa Rosa Consulting and The University of Texas MD ... go-live on the Epic platform in March of 2016. Both entities have already begun ... the contract by supporting Scheduling Appointment Conversion and the Go-Live. , “We are ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... ... Midlands counties served by Central Carolina Community Foundation (CCCF) in Columbia, South Carolina. ... address the pressing needs of flood victims – both short and long term. ...
(Date:10/9/2015)... ... October 09, 2015 , ... Most people assume that Chinese food is ... less meat. While noted T’ai Chi Master and integrative medicine guru Steven Aung, MD ... the two cuisines and that they potentially complement one another, with each supplying nutritional ...
(Date:10/9/2015)... ... October 09, 2015 , ... BrightStar ... recognized by Cabarrus County Active Living and Parks for its outstanding commitment to ... company’s dedication to consistently going above and beyond the call of duty, seniors ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... The Kitchenistas ... struggling against diabetes, obesity, and other health conditions related to food, has been selected ... City and at the Global Health Film Festival on October 30-31 in London, England. ...
Breaking Medicine News(10 mins):
... weight, there is a lot of confusion about what type of ... eat a low carbohydrate diet, a new study shows a low ... when the amount of food is not restricted. ,For the ... diet alone and in combination with exercise. They looked at body ...
... A certain biomarker in the blood may predict the risk ... disease //, according to a new study. ,Researchers conducted ... factor (PIGF) can predict risk for death or non-fatal heart ... member of the vascular growth factor family and it acts ...
... bacterial infection that affects the gums and bones supporting ... can not only reveal the general health of patients ... ,Researchers from Japan studied more than 7,450 men and ... 37 items, including cholesterol and C-reactive protein, which are ...
... a common complaint and one that causes excessive absence from ... patients aimed at returning them to normal activity levels. But ... the pain involved. ,A new study suggests people with ... it hurts.This study was conducted among the employees of an ...
... death syndrome or SIDS, could be significantly lowered by taking ... ,Researchers conducted studies in 20 centers in Europe, ... SIDS cases and 2,411 healthy infants to identify risks for ... were attributed to sleeping in the side or prone position. ...
... 2 diabetes used to be considered an adult disease, but ... Research has shown girls are affected more than boys. ... difference between girls and boys being diagnosed with type 2 ... study which aims to establish which children are insulin-resistant and ...
Cached Medicine News:
... assay is a sensitive, simple ... permits the detection of all ... and can distinguish between ... P. vivax . In addition, ...
Malaria Pf/Pv Assay Range...
ADVANTAGE MALARIA STIX is a visual, rapid and sensitive immunoassay for the qualitative differential detection of P.falciparum (P.f) and P.vivax (P.v) malaria in Human Blood only....
Malaria device / strip (2 line, P.f.-HRP2 Test)...
Medicine Products: